In another century and a half, the world, as we know it, will be greatly changed. This book foresees changes that most of us could scarcely dream of. But several earthly problems have not been resolved. One of these is the periodic emergence of infectious diseases that have evaded all efforts to prevent or control them. Enter Q-strain, an astoundingly pernicious mutation of Ebola virus which totally wipes out all humans on the Earth. There is time, however, to transport the very earliest stage of clones to the robotic station on the Moon. When the “all clear” for absence of the Ebola Q-strain mutant on the Earth has been biologically verified, these clones are given birth on the Moon and raised to adulthood by robotic guides and caretakers. The story then centers on the development of fourteen clones who must return a human presence to our now Ebola-free blue planet. This sounds like quite a challenge, and in fact, that’s just what it is.
Meet the Author
BRUCE MERCHANT, M.D., is a Research Physician in the Immunology and Pathology of Human responses to tumors and infectious diseases.. Bruce also holds a doctorate in Immunopathology from the University of Chicago. He was a lab researcher at the National Institutes of Health for a decade and then continued his research in Immunology, and Immunogenetics at the FDA for a second decade. He then moved mainly into Clinical Research and served first as the Director of Clinical studies at Hybritech, Inc. and later as Clinical V.P at Viagene, Inc. both Biotech companies in San Diego, California.
He then teamed up with James A. Taylor, Ph. D, to whom this book is dedicated. Together, they formed Merchant-Taylor International, Inc. (MTI), a consulting firm that over the past two decades has assisted over 200 Biotech and Small Pharma companies in moving their products forward through successive phases of Clinical Development.
Bruce still works full time in this consulting capacity. Many of MTI’s clients are developing therapies aimed at controlling infections or malignant tumors, and Bruce serves as the Clinical Monitor for several of these studies. He is also involved with two separate Clinical Studies, one which involves the use of Convalescent Immune Plasma (from Ebola survivors) and another employing a number of promising new pharmaceuticals which will be critically tested in Ebola patients in West Africa in an effort to control the current deadly epidemic.